Pharmaceutical group

Lavipharm

23 medicines3 countries

A group of 5 companies with 23 medicines in 3 countries.

Its medicines

Group structure

5 companies in 1 country

Greece1

Lavipharm S.A.Authorisation holder · 16 medicines

Headquarters not stated4

Lavipharm LabsAuthorisation holder · 4 medicines · listed in United States
LavipharmAuthorisation holder · 3 medicines · listed in United States
Lavipharm Pharm.products S.A.Authorisation holder · listed in Italy
Lavipharm Pharmaceutical Products Commercial and Industrial Societe AnonymeAuthorisation holder · listed in Italy

Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.

Medicines

Every medicine of every company in the group, current ones first.

23 medicines

Medicine	Substance	Country	Status	Authorised
CATAPRES-TTS-10.1mg/24hr · System	Clonidine	United States	Marketed	1984
CATAPRES-TTS-20.2mg/24hr · System	Clonidine	United States	Marketed	1984
CATAPRES-TTS-30.3mg/24hr · System	Clonidine	United States	Marketed	1984
DURFENTA 100 microgramos/HORA PARCHES TRANSDERMICOS EFG11,00 mg · Parche transdérmico	Fentanyl	Spain	Marketed	2012
DURFENTA 12 microgramos/HORA PARCHES TRANSDERMICOS EFG1,375 mg · Parche transdérmico	Fentanyl	Spain	Marketed	2012
DURFENTA 25 microgramos/HORA PARCHES TRANSDERMICOS EFG2,75 mg · Parche transdérmico	Fentanyl	Spain	Marketed	2012
DURFENTA 50 microgramos/HORA PARCHES TRANSDERMICOS EFG5,5 mg · Parche transdérmico	Fentanyl	Spain	Marketed	2012
DURFENTA 75 microgramos/HORA PARCHES TRANSDERMICOS EFG8,25 mg · Parche transdérmico	Fentanyl	Spain	Marketed	2012
Durogesic 100 µg/uur, pleisters voor transdermaal gebruikPleister voor transdermaal gebruik	Fentanyl	Netherlands	Authorised	1995
Durogesic 12 µg/uur, pleisters voor transdermaal gebruikPleister voor transdermaal gebruik	Fentanyl	Netherlands	Authorised	2004
Durogesic 25 µg/uur, pleisters voor transdermaal gebruikPleister voor transdermaal gebruik	Fentanyl	Netherlands	Authorised	1995
Durogesic 50 µg/uur, pleisters voor transdermaal gebruikPleister voor transdermaal gebruik	Fentanyl	Netherlands	Authorised	1995
Durogesic 75 µg/uur, pleisters voor transdermaal gebruikPleister voor transdermaal gebruik	Fentanyl	Netherlands	Authorised	1995
DUROGESIC MATRIX 100 microgramos/H PARCHES TRANSDERMICOS16,8 mg · Parche transdérmico	Fentanyl	Spain	Marketed	1998
DUROGESIC MATRIX 12 microgramos/H PARCHES TRANSDERMICOS2,1 mg · Parche transdérmico	Fentanyl	Spain	Marketed	2005
DUROGESIC MATRIX 25 microgramos/H PARCHES TRANSDERMICOS4,2 mg · Parche transdérmico	Fentanyl	Spain	Marketed	1998
DUROGESIC MATRIX 50 microgramos/H PARCHES TRANSDERMICOS8,4 mg · Parche transdérmico	Fentanyl	Spain	Marketed	1998
DUROGESIC MATRIX 75 microgramos/H PARCHES TRANSDERMICOS12,6 mg · Parche transdérmico	Fentanyl	Spain	Marketed	2002
FENTANYL-100100mcg/hr · Film, extended release	Fentanyl	United States	Marketed	2005
FENTANYL-2525mcg/hr · Film, extended release	Fentanyl	United States	Marketed	2005
FENTANYL-5050mcg/hr · Film, extended release	Fentanyl	United States	Marketed	2005
FENTANYL-7575mcg/hr · Film, extended release	Fentanyl	United States	Marketed	2005
TILKER CAPSULAS300 mg · Cápsula dura de liberación prolongada	Diltiazem	Spain	Withdrawn	2005

Sources and licences

Country	Medicines	Current	Past	Companies
Spain	11	10	1	Companies All medicines
United States	7	7	0	Companies All medicines
Netherlands	5	5	0	Companies All medicines

Compiled by Prognia from the public medicine and company registers below. Logos are not used.

Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.

Agencia Española de Medicamentos y Productos Sanitarios (CIMA)

Fuente de la información: AEMPS (CIMA).

Licence: AEMPS open data reuse with attribution

U.S. Food and Drug Administration (Drugs@FDA, openFDA)

Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.

Licence: Public domain (U.S. Government work)

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog

All 10 sources

College ter Beoordeling van Geneesmiddelen

College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.

Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim

ALIMS

ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.

Licence: Serbian Open Data Licence (sodl)

Läkemedelsverket, Sweden

Läkemedelsverket, Sweden, Förvaringstemperatur och hållbarhet, source extract 2026-10-20, acquired 2026-10-20T20:46:08.868635+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.

Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)

Läkemedelsverket, Sweden

Läkemedelsverket, Sweden, Läkemedelsprodukter, source extract 2026-10-20, acquired 2026-10-20T20:45:53.483733+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.

Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)

Report an error or request removal Corrections from the company itself are welcome.

Lavipharm

Group structure

Greece1

Headquarters not stated4

Medicines

Know your medicines, with the sources.

Lavipharm

Group structure

Greece1

Headquarters not stated4

Medicines

Know your medicines, with the sources.

Countries

Therapeutic areas

Top substances

Names in the registers

Sources and licences

At a glance

Work with Prognia

Other big groups

Group structure

🇬🇷Greece1

Headquarters not stated4

Medicines

Know your medicines, with the sources.

Group structure

🇬🇷Greece1

Headquarters not stated4

Medicines

Know your medicines, with the sources.

Countries

Therapeutic areas

Top substances

Names in the registers

Sources and licences

At a glance

Work with Prognia

Greece1

Greece1